{"filings":[{"id":1251036,"accession_number":"0001193125-26-281200","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-06-24T20:47:58+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Revelation Biosciences adopts bylaw amendments, authorizes reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended employment agreements for CEO & CFO: 2x salary+bonus severance on change in control, 18-mo COBRA, 3-year term.","Stockholders authorized reverse stock split up to 1:250 within one year, allowing Board to fix ratio without further approval.","Bylaws updated: universal proxy rule compliance, formal 'Cause' definition for officers/directors, removal only for cause due to classified board.","Elected Jennifer Carver as Class A director to serve until 2029 annual meeting; ratified Baker Tilly as auditor for FY2026.","Emergency succession framework added for CEO/CFO vacancies: CFO assumes CEO duties, CEO assumes CFO duties pending Board action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":780556,"accession_number":"0001193125-26-251784","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-06-01T21:26:39+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences releases updated corporate presentation without disclosed details","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["On June 1, 2026, the company made an updated corporate presentation publicly available.","Presentation is attached as Exhibit 99.1 but content was not reproduced in the filing.","No financial or operational changes, guidance, or material events were explicitly described."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95663,"accession_number":"0001193125-26-212064","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.","Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.","FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.","Received $6.7M net proceeds from January 2026 warrant inducement.","Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108883,"accession_number":"0001193125-26-116012","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["3.03","5.07","9.01"],"status":"ready","headline":"REVB stockholders approve share issuance above Exchange Cap; Class J warrants expiry set to March 2031","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of shares exceeding 20% of outstanding (For 4,033,345, Against 104,162, Abstain 34,228).","Class J Common Stock Warrants expiration extended to March 18, 2031 (5 years from stockholder approval on March 18, 2026).","Special Meeting quorum was 4,171,735 shares (39.8% of 10,492,469 outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108882,"accession_number":"0001193125-26-076833","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026","Net loss for FY2025 was $8.9 million ($23.95 per share) vs $15.0 million ($1,052.16 per share) in FY2024","Announced positive results from PRIME clinical study in late-stage chronic kidney disease patients","Reached agreement with FDA on a single adaptive Phase 2/3 study for Gemini to treat acute kidney injury","Clinical data on Gemini for AKI and CKD to be presented at International Conference on Advances in Critical Care Nephrology (March 29-April 1, 2026)"],"consensus_eps_estimate":null,"consensus_eps_actual":-23.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108881,"accession_number":"0001193125-26-027742","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Revelation Biosciences raises ~$7.3M via warrant exercise; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two holders exercised 8,544,999 pre-split Class I warrants at $0.86/share, gross proceeds ~$7.3M.","Company issued 17,089,998 pre-split new Class J warrants at $0.86/share, exercisable only after stockholder approval.","Net proceeds to fund clinical development and working capital.","Third investor withdrew; filing corrects earlier press release that had included them.","Roth Capital Partners received 8% cash fee of gross proceeds as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108880,"accession_number":"0001193125-26-018332","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences reaches FDA agreement on approval pathway for Gemini AKI treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed single Phase 2/3 adaptive study (~300 patients) can support NDA for Gemini in AKI.","Primary composite endpoint: death and/or need for dialysis; clinically relevant and objective.","Study design: randomized, double-blind, placebo-controlled; Part 1 dose finding, Part 2 Phase 3.","Company to engage CRO, advisors, and manufacture drug supply in 2026 before study start."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125342,"accession_number":"0001193125-25-306915","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["3.03","5.07","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.","CEO expects FDA meeting later in 2025 to discuss clinical/regulatory pathways for acute kidney injury.","Company plans to start Phase 2/3 AKI study in 2026, building manufacturing and CRO infrastructure.","Stockholders approved share issuance related to warrants; warrant expiration fixed to Dec 3, 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125341,"accession_number":"0001193125-25-269696","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.","Cash and equivalents $12.7M at Sept 30, 2025, up from $6.5M at Dec 31, 2024.","Received $9.6M gross proceeds from warrant inducement in September 2025.","Announced top-line results from PRIME clinical study; plans FDA meeting for Gemini registration path.","Net cash used in operations $6.3M for 9 months 2025 vs $14.6M in same period 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125340,"accession_number":"0001193125-25-256367","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Revelation Biosciences cancels Oct 29 special meeting due to voting technical issue; rescheduled to Dec 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting of Stockholders canceled due to technical difficulty preventing all shares from being voted.","Meeting originally set for Oct 15, adjourned to Oct 29, now canceled.","New record date set as October 29, 2025.","New Special Meeting of Stockholders scheduled for December 3, 2025.","Company to issue new proxy materials to stockholders of record as of new record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125339,"accession_number":"0001193125-25-240400","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Revelation Biosciences adjourns Oct 15 special meeting to Oct 29 due to no quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special Meeting adjourned because insufficient shares were present to form a quorum.","Meeting reconvenes virtually on October 29, 2025 at 12:00 p.m. ET.","Record date remains September 11, 2025; stockholders who already voted need not act.","Company urges all stockholders to vote before the new meeting date.","Proxy materials and additional voting instructions available on SEC's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142058,"accession_number":"0001193125-25-203750","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences raises $9.6M via immediate exercise of existing warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$9.6M gross proceeds from exercise of 13,065,000 existing warrants at $2.20/share.","Issued 13,065,000 new Class I warrants at same $2.20 price, exercisable after stockholder approval for 5 years.","Existing warrants covered 4,355,000 shares; new warrants cover 13,065,000 shares (higher dilution).","Proceeds to fund clinical development and working capital.","Roth Capital Partners acted as financial advisor for 8% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142057,"accession_number":"0001810560-25-000006","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences PRIME Phase 1b CKD study hits endpoints; Gemini reduces inflammation in high-background patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.","In patients with high background inflammation (≈50%), Gemini significantly reduced IL-1β, TNF-α, IL-6, IL-10, IL-1RA vs placebo (p<0.01) through 7 days.","Gemini restored normal cellular response to LPS/HMGB1 stimuli in high-background PBMCs, reversing immunoparalysis (IL-1β p<0.0001).","Company scheduled End of Phase 1 meeting with FDA later in 2025 to discuss advancement.","40 patients enrolled across 5 dose cohorts in 3 US clinics; data webcast on Sept 10, 2025 at 8:30 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142056,"accession_number":"0000950170-25-105485","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q2 net loss $2.4M; cash $5.2M; Gemini data due Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2025 was $2.4M ($7.01 per share), improved from $8.4M ($246.27) in Q2 2024.","Cash and equivalents $5.2M at June 30, 2025, down from $6.5M at Dec 31, 2024; funds operations through Dec 2025.","Completed dosing in Phase 1b Gemini study in CKD; topline data expected later Q3 2025.","Raised $4M gross proceeds from public offering in May 2025.","Cash used in operations was $4.7M in Q2 2025 vs. $5.3M in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142055,"accession_number":"0000950170-25-094789","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences effects 1-for-3 reverse stock split; PRIME Phase 1b enrollment expected to complete July 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-3 reverse stock split effective July 7, 2025; post-split shares ~1,534,599.","Split intended to regain Nasdaq minimum bid price compliance; CUSIP changed to 76135L705.","PRIME Phase 1b study of Gemini in CKD patients: enrollment expected to complete July 2025; topline data anticipated shortly after."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160029,"accession_number":"0000950170-25-089972","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Revelation Bio shareholders approve reverse split up to 1:250; Nevada reincorporation fails despite 89% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized at ratio 1:2 to 1:250, board to set exact ratio within one year.","Issuance of common stock under May 2025 Class H Warrants above 20% exchange cap approved.","Reincorporation from Delaware to Nevada failed (89% of votes cast in favor, but not enough outstanding shares).","Lakhmir Chawla elected Class C director; advisory votes on exec compensation and frequency (3 years) passed.","Baker Tilly US ratified as auditor for FY2025; CEO presentation given but details not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160028,"accession_number":"0000950170-25-081604","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences closes $4M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4M from sale of 3,640,000 shares (or pre-funded warrants) plus warrants for up to 14,560,000 shares.","Warrants exercise price $1.10/share, exercisable after stockholder approval, expire 5 years from initial exercise date.","Net proceeds to fund Phase 1b study, clinical drug supply manufacture, preclinical work, and general corporate purposes.","Roth Capital Partners acted as sole placement agent; offering closed May 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160027,"accession_number":"0000950170-25-078340","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Director George Tidmarsh resigns from Revelation Biosciences board to avoid conflict of interest","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Tidmarsh, MD, PhD resigned from the Board on May 23, 2025, to avoid conflict with new US governmental agency work.","Board size reduced from 5 to 4; Lakhmir Chawla, MD reclassified as Class C Director.","Resignation was not due to any disagreement with the company's operations, policies, or practices.","Tidmarsh served as a Class C Director for 5 years; term was set to expire at the 2025 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160026,"accession_number":"0000950170-25-067043","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q1 net loss $2.1M; cash only to June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $3.7M at March 31, 2025, down from $6.5M at Dec 31, 2024.","Net loss $2.1M ($2.11 per share) vs $2.7M ($39.37 per share) in Q1 2024.","Operating cash burn $2.8M in Q1 2025, same as Q1 2024.","Management says current cash sufficient only through June 2025.","New indication for Gemini in severe burns; topline PRIME Phase 1b data expected summer 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178361,"accession_number":"0000950170-25-040294","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gemini priming attenuates inflammation in human PBMCs; Phase 1b data expected mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gemini significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines vs. placebo in PBMCs challenged with HMGB-1 and LPS.","Revelation anticipates demonstrating same protective effect in cells from CKD patients in ongoing Phase 1b PRIME study.","Top-line safety, tolerability, and cellular protection data from Phase 1b expected by mid-2025.","Results support future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.","CEO James Rolke called results 'game-changing' for Gemini's potential in target indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178360,"accession_number":"0000950170-25-034689","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences reports FY2024 net loss of $15.0M; cash at $6.5M, expects to fund ops into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $1.7M ($4.98/share) vs $2.2M ($133.64/share) in Q4 2023.","FY2024 net loss $15.0M ($87.68/share) vs $0.1M ($8.44/share) in FY2023.","Cash and equivalents $6.5M at Dec 31, 2024, down from $12.0M a year ago.","Operating cash burn $18.3M in FY2024 vs $7.3M in FY2023.","Phase 1b PRIME study of Gemini in CKD patients dosing; topline data expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178359,"accession_number":"0000950170-25-025626","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences regains Nasdaq compliance and advances PRIME Phase 1b CKD study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed REVB common stock meets minimum bid price and all continued listing requirements.","Company cannot use 180-day grace period if bid price falls below $1.00 again; would receive delisting letter but may request hearing.","PRIME Phase 1b study of Gemini IV in Stage 3-4 CKD patients has commenced, enrolling up to 40 patients across 5 cohorts.","CEO James Rolke highlighted Nasdaq listing for liquidity, capital access, and talent retention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178358,"accession_number":"0000950170-25-017882","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences posts updated corporate presentation; no new specific data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated February 10, 2025 made available on company website; content not summarized in the 8-K.","Investors must access the company's investor relations page to view the presentation; no material updates disclosed in the filing.","No changes to financial outlook, pipeline, or guidance were announced in this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178357,"accession_number":"0000950170-25-011197","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Revelation Biosciences effects 1-for-16 reverse stock split; shares outstanding cut to ~522K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective Jan 28, 2025, at 1-for-16 ratio; no fractional shares issued.","Approximately 522,281 shares of common stock outstanding after the split.","Proportionate adjustments made to all outstanding equity awards and warrants, except certain warrants with price reset features.","Common stock continues to trade under symbol REVB on Nasdaq; new CUSIP 76135L606.","Split approved by stockholders at Jan 17, 2025 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178356,"accession_number":"0000950170-25-007303","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Revelation starts Phase 1b Gemini CKD study; shareholders approve reverse split but reincorporation fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRIME Phase 1b study of Gemini in Stage 3-4 CKD patients started; dosing mid-Feb, topline data expected mid-year.","Shareholders approved reverse stock split (range 1:2 to 1:50) with board discretion; 3.96M for, 163K against.","Change of domicile from Delaware to Nevada failed despite 97% of votes present in favor (2.96M for, 74K against) due to insufficient affirmative votes of outstanding shares.","Shareholders approved issuance of shares under warrants (Dec 2024) exceeding 20% threshold; also approved meeting adjournment.","1,089,301 broker non-votes affected the change-of-domicile and warrant issuance proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178355,"accession_number":"0000950170-25-002828","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Nasdaq grants Revelation continued listing subject to reverse split and $1 price by Feb 14, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel granted continued listing; must effect reverse stock split by Jan 31, 2025.","Must maintain $1.00 bid price for 10 consecutive trading days by Feb 14, 2025.","Regained compliance with Nasdaq equity requirement (Rule 5550(b)(1)).","Company raised $4M from warrant exercise in December 2024.","FDA accepted Gemini IND; Phase 1b study in chronic kidney disease expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195016,"accession_number":"0000950170-24-135895","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences regains compliance with Nasdaq stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reported stockholders' equity of $2.67M as of Sep 30, 2024, meeting the $2.5M minimum.","Entered warrant inducement letters on Dec 3, 2024; 4,064,040 warrants exercised at $1.00/share.","Gross proceeds from warrant exercises approximately $4.1M; equity now ~$6.0M, cash ~$7.1M.","Company believes it is compliant with Nasdaq Listing Rule 5550(b)(1) as of Dec 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195015,"accession_number":"0000950170-24-134064","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"FDA accepts IND for Gemini Phase 1b CKD study; REVB raises ~$4.1M from warrant exercises","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted IND for Gemini (trained immunity) for Phase 1b study in up to 40 CKD patients; primary endpoint safety/tolerability.","Existing Class E warrants exercised at $1.00/share for ~$4.1M gross proceeds; new Class F and G warrants issued as inducement.","Proceeds to fund clinical trials for GEM-AKI, GEM-CKD, GEM-PSI and working capital.","New Class F warrants (2yr, $1.00) and Class G warrants (5yr, $1.00) subject to stockholder approval; include cashless exercise provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195014,"accession_number":"0000950170-24-124141","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences reports Q3 net loss of $2.2M; cash $6.5M into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024: $2.2M ($0.84 per share) vs $2.6M loss in Q3 2023; nine-month net loss $13.3M vs net income $2.1M in prior year.","Cash and cash equivalents $6.5M as of Sep 30, 2024, down from $12.0M at Dec 31, 2023; raised $3.8M from warrant exercise in Aug 2024.","Clinical-stage biotech advancing Gemini; expects FDA IND acceptance to start Phase 1b in CKD patients; cash runway into 2025.","Net cash used in operations nine months: $14.6M vs $5.3M in 2023; cash burn increased significantly."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195013,"accession_number":"0000950170-24-115955","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Revelation Biosciences receives Nasdaq deficiency notices for bid price and stockholders' equity; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified REVB of non-compliance with $1.00 minimum bid price rule as of October 16, 2024.","Company not eligible for 180-day cure period due to reverse stock splits exceeding 250:1 cumulative ratio over two years.","Also cited for stockholders' equity deficiency (rule 5550(b)(1)), but company believes it satisfied requirement as of Sept 30, 2024 via Q3 financing.","Company will request a hearing before Nasdaq hearings panel to stay any suspension or delisting pending appeal.","Trading of common stock (REVB) and warrants (REVBW) continues on Nasdaq Capital Market for now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211305,"accession_number":"0000950170-24-109998","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences reports Gemini induces dose-dependent IL-10 increases up to 309-fold in Phase 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gemini induced statistically significant (p<0.05) dose-dependent IL-10 increases: 27-fold (low), 162-fold (mid), 309-fold (high) vs placebo at 2 hours.","No significant increase in pro-inflammatory IL-1b and TNF-a, confirming TLR4 binding unique to Gemini.","Data consistent with prior preclinical acute kidney injury models; supports potential in preventing AKI after cardiac surgery.","Company plans to initiate Phase 1b study in late 2024.","CEO James Rolke highlighted potential to fine-tune innate immune response and speed healing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211304,"accession_number":"0000950170-24-100550","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences raises ~$3.8M via warrant exercises; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class D warrant holders exercise 2,548,060 shares at reduced price of $1.50/share, gross proceeds ~$3.8M.","New Inducement Warrants issued to purchase up to 5,096,120 shares at $1.00/share, exercisable for 5 years.","Net proceeds to fund GEM-AKI, GEM-CKD, GEM-PSI clinical trials and working capital.","Roth Capital Partners paid ~$267,546 advisory fee; exercise prices of certain Class C/D warrants adjusted to $1.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211303,"accession_number":"0000950170-24-098505","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Revelation Biosciences warns of delisting risk; stockholders' equity only $1.14M vs $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Aug 14, 2024, citing insufficient stockholders' equity of $1,140,421 vs required $2.5M.","Also failed alternative listing standards (market value of listed securities ≥$35M or net income from continuing ops $500K).","Company has 45 days to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.","No immediate effect on trading; common stock and warrants continue trading under REVB and REVBW.","Company intends to take reasonable measures but no assurance of extension or regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211302,"accession_number":"0000950170-24-094788","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q2 net loss $8.4M; cash $12.1M, plans Phase 1b","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2024 of $8.4M ($5.13 per share) vs $1.4M loss in Q2 2023.","Net loss for H1 2024 of $11.1M ($8.13 per share) vs net income of $4.7M in H1 2023.","Cash and equivalents $12.1M as of June 30, 2024, up from $12.0M at Dec 31, 2023.","Completed Phase 1 dosing of Gemini; safety endpoint met with biomarker activity.","Phase 1b study in CKD patients expected to start in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211301,"accession_number":"0000950170-24-089966","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences faces $7.3M judgment in LifeSci Capital lawsuit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court entered summary judgment against Revelation Biosciences for ~$7.3M in unpaid banking and advisory fees plus interest.","Judgment adopted Magistrate Judge's December 2023 recommendation; company had contested fee obligation from pre-merger contracts.","Company states it has sufficient cash to satisfy the judgment and expects no immediate impact on clinical trial programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229872,"accession_number":"0000950170-24-076761","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences adjusts warrant exercise price to $2.39 per share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class C warrants now exercisable for 1/30th of a common share at $2.39 per share.","Class D warrants now exercisable for one common share at $2.39 per share.","Cede & Co. cannot process exercises at adjusted price until DTC system updates.","Warrant holders may exercise by sending Notice to Continental Stock Transfer with DWAC instructions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229871,"accession_number":"0000950170-24-061061","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Revelation Bio shareholders approve director elections, equity plan increase, auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James Rolke (122,822 for) and Jess Roper (122,543 for) elected as Class B directors; 461,538 broker non-votes.","Approved amendment to 2021 Equity Incentive Plan increasing reserved shares from 21,623 to 163,294 (107,447 for, 42,981 against).","Ratified Baker Tilly US, LLP as auditor for FY2024 with 595,879 for, 18,558 against.","Quorum achieved with 614,695 shares present (greater than 1/3 of 1,632,935 outstanding shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229870,"accession_number":"0000950170-24-057927","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q1 net loss $2.7M; cash $14.6M sufficient through 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.7M ($2.46 per share) for Q1 2024, compared to net earnings of $6.2M in Q1 2023, driven by change in warrant liability.","Cash and cash equivalents $14.6M as of March 31, 2024, up from $12.0M at December 31, 2023.","Net cash used in operating activities was $2.8M, up from $1.6M YoY, due to clinical study expenses for GEM-AKI and GEM-SSI.","Company believes current cash is sufficient to fund operations through 2024 based on current projections."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248348,"accession_number":"0000950170-24-035376","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences FY2023 net loss narrows to $0.1M; cash $12.0M through 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Year-end cash $12.0M vs $5.3M; company believes sufficient to fund operations through 2024.","Net loss for FY2023 $0.1M (EPS -$0.53) vs $10.8M loss ($149.20 EPS) in 2022, due to $8.3M warrant liability gain.","Q4 2023 net loss $2.2M ($8.33 EPS) vs $1.2M loss ($15.61 EPS) in Q4 2022; operating cash burn $2.0M.","Completed $6.2M public offering; began Phase 1 study of Gemini; presented positive preclinical AKI data.","Net cash used in operations for FY2023 was $7.3M, down from $11.2M in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248347,"accession_number":"0000950170-24-029611","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Revelation presents positive preclinical Gemini data for AKI; Phase 1 initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gemini (PHAD) significantly reduced serum BUN, creatinine, and urine CRP in rat AKI model at 0.35 mg/kg (p<0.05).","Reduced cortical/medullary tubular necrosis and neutrophilic inflammation at 0.35 mg/kg dose.","Phase 1 clinical studies for Gemini initiated in February/March 2024.","Data presented at the 29th Intl Conference on Advances in Critical Care Nephrology on March 12, 2024.","Gemini is a synthetic TLR4 agonist that preconditions innate immunity to attenuate pro-inflammatory response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248346,"accession_number":"0000950170-24-012748","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences raises $6.2M in public offering, regains Nasdaq bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$6.2M from sale of 128,470 shares and 1,236,530 pre-funded warrants, plus 2,730,000 Class D warrants at $4.53 combined price.","Class D warrants exercisable at $4.53/share, expire in 5 years; pre-funded warrants at $0.0001/share, no expiration.","Net proceeds to fund Phase 1a/1b studies for GEM-SSI (surgical site infection) and GEM-AKI (cardiac surgery AKI), plus preclinical GEM-CKD work.","Nasdaq confirmed on Feb 8, 2024 that REVB regained compliance with minimum $1.00 bid price rule after 11 consecutive trading days above $1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248345,"accession_number":"0000950170-24-008972","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Revelation Biosciences posts updated corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated Jan 30, 2024, posted on company website; no financial or pipeline specifics in filing.","Company focuses on developing innovative therapeutics for unmet medical needs.","No guidance, milestones, or material events announced in the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248344,"accession_number":"0000950170-24-006510","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["3.03","5.03"],"status":"ready","headline":"Revelation Biosciences effects 1-for-30 reverse stock split, ~210K shares outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at Jan 17 special meeting; board set ratio at 1-for-30.","Reverse split effective 12:01 a.m. ET on Jan 25, 2024; common stock continues trading under REVB.","Post-split shares outstanding ~209,911; no fractional shares, rounding up to whole shares.","Outstanding equity awards and warrants proportionally adjusted for the 1-for-30 ratio.","New CUSIP for common stock: 76135L507."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248343,"accession_number":"0000950170-24-006051","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Revelation Biosciences shareholders approve reverse stock split (1:2 to 1:50)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized with ratio range 1-for-2 to 1-for-50; board to set exact ratio within one year.","Proposal 1 votes: 1,410,313 For, 831,173 Against, 2,562 Abstain.","Proposal 2 to adjourn if needed also approved: 1,676,035 For, 551,758 Against, 16,255 Abstain.","Special Meeting held Jan 17, 2024; quorum of 2,244,048 shares of 6,297,303 outstanding.","Board has sole discretion to implement split at any time within one year without further shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265839,"accession_number":"0000950170-23-063019","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences reports Q3 2023 net loss of $2.6M; cash $14.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.6M ($0.42/share) vs loss $1.2M ($1.91/share) in Q3 2022; nine-month net income $2.1M on $8.3M warrant gain.","Cash and equivalents $14.0M at Sep 30, 2023, up from $5.3M at Dec 31, 2022; runway through Sep 2024.","Operating cash burn for nine months 2023 was $5.3M vs $10.3M in 2022, driven by lower clinical study expenses.","Gemini preclinical data showed significant mobilization of neutrophils, monocytes, lymphocytes and upregulation of IL-10, NGAL, IL-6.","Phase 1 clinical study of Gemini expected to begin near end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265838,"accession_number":"0000950170-23-053115","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences reports preclinical Gemini data showing biomarker activity; Phase 1 study planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gemini showed dose-dependent white blood cell mobilization and cytokine upregulation (IL-10, NGAL, IL-6) in healthy animal models.","Data supports Gemini as a preventative therapy for infection and acute kidney injury; key biomarkers confirmed.","Company plans to initiate a Phase 1 healthy volunteer study later this year, with full results to be published.","Second dose of Gemini demonstrated attenuated IL-6 response indicating trained immunity; two-dose regimen being evaluated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265837,"accession_number":"0000950170-23-051141","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Revelation Biosciences appoints Lakhmir Chawla to board; Curt LaBelle resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Curt LaBelle M.D. resigned from Board on Sept 27, 2023, not due to any disagreements.","Lakhmir Chawla M.D. appointed as Class C director to fill vacancy, effective same date.","Dr. Chawla is CEO of Stavro Medical; former CMO at Silver Creek Pharma and La Jolla Pharmaceutical.","He will serve on Compensation and Nominations & Corporate Governance Committees.","No transactions requiring Item 404(a) disclosure between Dr. Chawla and the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283057,"accession_number":"0000950170-23-041889","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q2 2023 net loss $1.4M; cash $15.7M; 6-month net income $4.7M on warrant gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $15.7M as of June 30, 2023, up from $5.3M at Dec 31, 2022.","Net loss for Q2 2023 was $1.4M ($0.25 per share) vs $1.8M ($4.16 per share) in Q2 2022.","Net income for 6 months ended June 30, 2023 was $4.7M ($1.61 basic EPS) vs net loss of $8.5M in prior period, driven by $8.2M warrant liability gain.","Net cash used for operating activities for 6 months ended June 30, 2023 was $3.6M, down from $8.5M year-over-year.","Management believes current cash sufficient to fund operations through June 2024; decreased clinical study expenses contributed to lower losses."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283056,"accession_number":"0000950170-23-041840","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Revelation Biosciences receives Nasdaq bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified REVB on Aug 8, 2023 of noncompliance with minimum $1.00 bid price rule for 30 consecutive business days.","Company has a 180-day grace period until Feb 5, 2024 to regain compliance; common stock must close at $1.00+ for 10 consecutive days.","If not cured, may be eligible for an additional 180-day extension pending meeting other listing standards and reverse stock split if needed.","Noncompliance has no immediate impact on trading; stock continues listed on Nasdaq Capital Market.","Company is evaluating options to maintain listing including potential reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283055,"accession_number":"0000950170-23-033021","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Revelation Biosciences stockholders elect directors, approve equity plan increase, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 2,309,314 shares (>1/3 of 5,773,983 outstanding) present or proxy.","Directors Jennifer Carver (1,281,109 for) and Curt LaBelle (1,280,290 for) elected to Class A.","Approved amendment to 2021 Equity Incentive Plan: shares reserved increased from 68,288 to 648,678 (1,124,336 for).","Ratified Baker Tilly US, LLP as auditor for fiscal year ending Dec 31, 2023 (1,981,630 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4260177.594339622,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-07-14T23:59:59+00:00|283055"}